Wealthfront Advisers LLC Sells 4,150 Shares of Cencora, Inc. (NYSE:COR)

Wealthfront Advisers LLC lessened its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 22.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,239 shares of the company's stock after selling 4,150 shares during the period. Wealthfront Advisers LLC's holdings in Cencora were worth $3,199,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in COR. JFS Wealth Advisors LLC grew its holdings in shares of Cencora by 63.0% during the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after purchasing an additional 46 shares in the last quarter. SBI Securities Co. Ltd. bought a new stake in Cencora during the fourth quarter worth about $30,000. Householder Group Estate & Retirement Specialist LLC grew its stake in Cencora by 85.2% during the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock worth $33,000 after buying an additional 69 shares in the last quarter. Kentucky Trust Co bought a new position in Cencora in the 4th quarter valued at about $33,000. Finally, WASHINGTON TRUST Co increased its holdings in Cencora by 37.7% in the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after buying an additional 46 shares during the period. Institutional investors own 97.52% of the company's stock.

Insider Activity at Cencora

In related news, EVP Silvana Battaglia sold 1,678 shares of the business's stock in a transaction on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the transaction, the executive vice president now owns 20,329 shares in the company, valued at $4,649,648.88. The trade was a 7.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Robert P. Mauch sold 4,970 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $255.00, for a total transaction of $1,267,350.00. Following the sale, the chief executive officer now directly owns 51,070 shares in the company, valued at $13,022,850. This trade represents a 8.87 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 13,648 shares of company stock worth $3,382,462 over the last ninety days. Insiders own 10.80% of the company's stock.

Remove Ads

Cencora Trading Up 1.1 %

NYSE COR traded up $2.91 on Monday, hitting $260.98. The company's stock had a trading volume of 1,238,931 shares, compared to its average volume of 1,352,236. The firm has a market cap of $50.61 billion, a PE ratio of 37.12, a PEG ratio of 1.31 and a beta of 0.51. The company's 50-day moving average is $247.59 and its 200 day moving average is $239.15. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $263.70.

Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.84%. The ex-dividend date of this dividend was Friday, February 14th. Cencora's dividend payout ratio is currently 31.29%.

Wall Street Analyst Weigh In

COR has been the topic of a number of recent analyst reports. Evercore ISI lifted their price objective on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research note on Thursday, February 6th. StockNews.com raised shares of Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Mizuho initiated coverage on shares of Cencora in a report on Wednesday, December 4th. They set an "outperform" rating and a $280.00 price target on the stock. Wells Fargo & Company upped their price objective on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research report on Friday. Finally, JPMorgan Chase & Co. raised their target price on shares of Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research report on Friday, January 24th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $280.20.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.